Interstitial Low Dose Rate Brachytherapy for Prostate Cancer - A Focus on Intermediate- and High-risk Disease

Clinical Oncology

Volumn 18, Issue 7, 2006, Pages 513-518

  Khaksar, S J ^a   Langley, S E M ^a   Lovell, D ^b   Laing, R W ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Intermediate and high risk disease; prostate brachytherapy; survival

Indexed keywords

ANTIANDROGEN; IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; ANDROGEN THERAPY; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL;

EID: 33746394264     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.05.005     Document Type: Article

References (30)

1. Nguyen P.L., Schultz D., Renshaw A.A., et al. The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. Urol Oncol 22 (2004) 295-299
2. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
3. Zelefsky M.J., Hollister T., Raben A., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47 (2000) 1261-1266
4. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
5. Kollmeier M., Stock R., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Biol 57 (2003) 645-653
6. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
7. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
8. Henderson A., Cahill D., Laing R.W., and Langley S.E. (125)Iodine prostate brachytherapy: outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics. BJU Int 90 (2002) 567-572
9. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
10. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
11. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
12. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 280 (1998) 969-974
13. Brachman D.G., Thomas T., Hilbe J., and Beyer D.C. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 48 (2000) 111-117
14. Potters L., and Freeman K. Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer. J Am Med Assoc 281 1584 (1999) 1585-1586
15. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
16. Critz F.A., Levinson A.K., Williams W.H., et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 49 (1997) 322-326
17. Kupelian P., Kuban D., Thames H., et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61 (2005) 415-419
18. Al-Qaisieh B., Carey B., Ash D., and Bottomley D. The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 397-399
19. Langley S.E.M., and Laing R.W. Prostate brachytherapy has come of age: a review of the technique and results. Br J Urol 89 (2002) 1-14
20. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
21. Blasko J.C., Grimm P.D., Sylsvester J.E., and Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57 (2000) 273-278
22. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
23. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
24. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
25. Pilepich M.V., Winter K., and John M.J. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced prostate cancer. Int J Radiat Biol 50 (2001) 1243-1252
26. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. J Am Med Assoc 292 (2004) 821-827
27. D'Amico A.V., Renshaw A.A., Cote K., et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 22 (2004) 3726-3732
28. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
29. Merrick G.S., Butler W.M., Wallner K.E., et al. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation. Cancer J 10 (2004) 54-60
30. D'Amico A.V. Perineural invasion as a predictor of PSA outcome following local therapy for patients with clinically localized prostate cancer. Cancer J 7 (2001) 375-376